Three-arm randomized phase II clinical study of irofulven/prednisone, irofulven/capecitabine/prednisone or mitoxantrone/prednisone in docetaxel-pretreated hormone-refractory prostate cancer patients
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Irofulven (Primary) ; Capecitabine; Mitoxantrone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Eisai Medical Research
- 02 Jun 2007 Results data presented at ASCO 2007 (1078679).
- 04 Dec 2006 Status change
- 08 Nov 2005 New trial record.